ATE218342T1 - Verwendung von rifaximin als medikament zur behandlung von durch cryptosporidiose verursachten diarrhoeen - Google Patents

Verwendung von rifaximin als medikament zur behandlung von durch cryptosporidiose verursachten diarrhoeen

Info

Publication number
ATE218342T1
ATE218342T1 AT98101081T AT98101081T ATE218342T1 AT E218342 T1 ATE218342 T1 AT E218342T1 AT 98101081 T AT98101081 T AT 98101081T AT 98101081 T AT98101081 T AT 98101081T AT E218342 T1 ATE218342 T1 AT E218342T1
Authority
AT
Austria
Prior art keywords
cryptosporidiosis
rifaximin
treatment
medication
diarrhea caused
Prior art date
Application number
AT98101081T
Other languages
English (en)
Inventor
Patrizio Ferrari
Antonella Ferrieri
Pietro Caramello
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Application granted granted Critical
Publication of ATE218342T1 publication Critical patent/ATE218342T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
AT98101081T 1997-02-14 1998-01-22 Verwendung von rifaximin als medikament zur behandlung von durch cryptosporidiose verursachten diarrhoeen ATE218342T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT97BO000064A IT1290679B1 (it) 1997-02-14 1997-02-14 Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.

Publications (1)

Publication Number Publication Date
ATE218342T1 true ATE218342T1 (de) 2002-06-15

Family

ID=11341939

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98101081T ATE218342T1 (de) 1997-02-14 1998-01-22 Verwendung von rifaximin als medikament zur behandlung von durch cryptosporidiose verursachten diarrhoeen

Country Status (12)

Country Link
US (1) US5886002A (de)
EP (1) EP0858804B1 (de)
JP (1) JP4848083B2 (de)
KR (1) KR100436243B1 (de)
CN (1) CN1115146C (de)
AT (1) ATE218342T1 (de)
DE (1) DE69805672T2 (de)
DK (1) DK0858804T3 (de)
ES (1) ES2178048T3 (de)
HU (1) HU224592B1 (de)
IT (1) IT1290679B1 (de)
PT (1) PT858804E (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
KR20060006953A (ko) * 2003-04-30 2006-01-20 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 치환된 카르복실산
US20060210492A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ES2538478T3 (es) * 2006-08-02 2015-06-22 Salix Pharmaceuticals, Inc. Métodos para el tratamiento de enteritis por radiación
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
KR20110071096A (ko) 2008-09-26 2011-06-28 아스카 세이야쿠 가부시키가이샤 기능성 소화관 장해의 예방 및/또는 치료제
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
EP2350096B1 (de) 2008-10-02 2019-12-11 Salix Pharmaceuticals, Ltd. Verfahren zur behandlung von hepatischer enzephalopathie
CA2781580A1 (en) 2009-11-23 2011-05-26 Cipla Limited Topical foam composition
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
JP6092629B2 (ja) * 2010-03-10 2017-03-08 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミン使用準備済懸濁液
CA2810598A1 (en) 2010-09-13 2012-03-22 Cipla Limited Pharmaceutical composition
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
KR102362719B1 (ko) 2014-05-12 2022-02-14 알파시그마 에스.피.에이. 리팍시민의 신규한 용매화 결정 형태, 생산물, 조성물 및 이의 용도
WO2016003536A1 (en) * 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Methods for retreating irritable bowel syndrome (ibs)
US20180021297A1 (en) * 2015-02-26 2018-01-25 Jaguar Health, Inc. Use Of Croton- Or Calophyllum-Derived Proanthocyanidin Polymers Or Botanical Extracts In Combination With Rifaximin For The Treatment Of Diarrhea In Non-Human Animals
CA2988930A1 (en) * 2015-06-10 2016-12-15 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
ES2979135T3 (es) 2016-10-14 2024-09-24 Cipla Ltd Composiciones farmacéuticas que comprenden rifaximina

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264494B1 (it) * 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter

Also Published As

Publication number Publication date
US5886002A (en) 1999-03-23
PT858804E (pt) 2002-10-31
HUP9800115A1 (hu) 1999-06-28
HU9800115D0 (en) 1998-03-30
HU224592B1 (hu) 2005-11-28
HUP9800115A3 (en) 2000-04-28
CN1115146C (zh) 2003-07-23
KR100436243B1 (ko) 2004-08-25
DK0858804T3 (da) 2002-07-08
DE69805672T2 (de) 2003-01-23
ES2178048T3 (es) 2002-12-16
ITBO970064A0 (it) 1997-02-14
DE69805672D1 (de) 2002-07-11
JP4848083B2 (ja) 2011-12-28
CN1214244A (zh) 1999-04-21
KR19980071348A (ko) 1998-10-26
JPH10226645A (ja) 1998-08-25
EP0858804B1 (de) 2002-06-05
ITBO970064A1 (it) 1998-08-14
EP0858804A1 (de) 1998-08-19
IT1290679B1 (it) 1998-12-10

Similar Documents

Publication Publication Date Title
ATE218342T1 (de) Verwendung von rifaximin als medikament zur behandlung von durch cryptosporidiose verursachten diarrhoeen
DE69635959D1 (de) Behandlung negativer und kognitiver symptome der schizophrenie mit antagonisten der glycinaufnahme
DE69429717D1 (de) Heterocyclische verbindungen und ihre herstellung und verwendung
ATE339968T1 (de) Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit
DE60237635D1 (de) Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose
MY131458A (en) Pyrolopyrimidine compounds
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
TR199902538T2 (xx) Yeni bile�imler.
TR200001203T2 (tr) Yeni birleşik maddeler
IL110031A0 (en) Phenyl heterocycles, their manufacture and pharmaceutical compositions containing them
ATE337316T1 (de) Imidazo 1,2-aöpyridin-derivate zur prophylaxe und behandlung von herpes-infektionen
TNSN99001A1 (fr) Indoles 2,3-substitues servant d'agents anti-inflammatoires et analgesiques
ATE235244T1 (de) Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten
IL104261A0 (en) Azacyclic and azabicyclic compounds,their preparation and pharmaceutical compositions containing them
ES2195397T3 (es) Quinazolin-2,4-dionas sustituidas en posicion 7 utiles como agentes antibacterianos.
TR199700999T1 (xx) Askomisinler.
BR0111989A (pt) Peptìdeos, composições e processos para o tratamento de burkholderia cepacia
BR9803385A (pt) AtropisÈmeros de 2,3-dissubstituìdo-(5,6)-heteroaril condensado-pirimidin-4-onas.
TR200000907T2 (tr) Nötrofil elastaz inhibitörleri olarak pirolopirolon türevleri.
ATE199321T1 (de) Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen.
DE69710111D1 (de) Behandlung und Prophylaxe von Pankreatitis
MX9709451A (es) Derivados de benzisoxazol e indazol como agentes antipsicoticos.
DE69526584D1 (de) Verwendung von immunosuppressiva zur behandlung der schizophrenie
MA27905A1 (fr) Pyrazolines utilisees comme antagonistes par-1 pour traiter des maladies cardio-vasculaires
HUT73231A (en) Pharmaceutical compositions with 17-beta-monosubstituted-carbamoyl-4-aza-5-alpha-androst-1-en-3-ones for treatment of chronic prostatitis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification